Thursday, April 20, 2017 2:57:18 PM
"It is gratifying that we have expanded our small molecule portfolio in such a way that we have reduced risk in the development program so early in the process," says David Koos, Ph.D., CEO and Chairman of Regen. "With ChemDiv, Inc. as our key partner, we are moving at a rapid pace towards our goal of having clinical candidate drugs in fourth quarter of 2017."
The reason for the greed is obvious. Regen will have a major partner before this goes much further. I believe the biggest Pharma in the world (Novartis) is behind its competitors in the Immunology field and this will help them catch up. IMO of coarse.
Best regards!
Schuller.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM